Theriva Biologics, Inc. (TOVX)

Theriva Biologics' stock has experienced significant fluctuations, including a substantial decline of 85.00% between February 3, 2025, and January 30, 2026, and a 99% depreciation over the past five years. On October 24, 2025, TOVX experienced unusual trading activity, gaining 0.88% with high volatility and trading volume. In September 2025, the company saw a 27.7% drop in short interest. The company reported its Q3 2025 operational highlights and financial results on November 12, 2025. More recently, on February 6, 2026, the stock price fell by -0.90%, though it was up by 0.56% over the preceding two weeks, and saw a +10.06% change on February 6, 2026, and a +14.23% change on February 5, 2026.

The demand for Theriva Biologics' products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by factors such as the progress of clinical trials, potential regulatory approvals, and the prevalence of the diseases its therapies aim to treat.

Theriva Biologics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland, focused on developing biologic therapies for unmet medical needs within the Healthcare sector, specifically in the Pharmaceutical Products sub-industry. Its major product candidates include VCN-01, an oncolytic adenovirus in clinical trials for various cancers; VCN-11, another oncolytic adenovirus in preclinical development for solid tumors; SYN-004 (ribaxamase), designed to degrade certain intravenous beta-lactam antibiotics within the gastrointestinal tract; SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase; SYN-006, a clinical-stage product aimed at preventing aGVHD and infection by carbapenem-resistant enterococci; and SYN-007, a clinical-stage product for preventing antibiotic-associated diarrhea with oral ß-lactam antibiotics.

Theriva Biologics, Inc. is headquartered in Rockville, Maryland, and develops therapeutics for the U.S. market. It has a subsidiary, Theriva Biologics, S.L., involved in developing its oncolytic adenovirus platform. The company also collaborates with institutions in the United States and Spain.

Theriva Biologics has received a "Hold" consensus rating from Wall Street research analysts in the past year. MarketBeat indicates that Theriva Biologics scored higher than 2% of companies evaluated. TradeSmith's Health Indicator has placed TOVX in the "Red zone" for over two months, signaling unhealthy financial health.

Theriva Biologics, Inc. has 26 institutional owners and shareholders who collectively hold 845,002 shares. Major institutional shareholders include Vanguard Group Inc, UBS Group AG, Ikarian Capital, LLC, Two Sigma Investments, Lp, Virtu Financial LLC, Jane Street Group, Llc, Boothbay Fund Management, Llc, XTX Topco Ltd, Geode Capital Management, Llc, and Two Sigma Advisers, Lp. Institutional ownership accounts for approximately 2.37% to 3.41% of the shares outstanding, while individual and insider ownership stands at about 2.10%. Insider sentiment has been positive, marked by high-impact open-market purchases from insiders, with collective insider purchases totaling $918.3K and no sales across 34 transactions over the last year.